These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 6113835)

  • 1. Additional studies on side effects of melperone in long-term therapy for 1 to 15 years in psychiatric patients.
    Kirkegaard A; Kirkegaard G; Geismar L; Christensen I
    Arzneimittelforschung; 1981; 31(4):737-40. PubMed ID: 6113835
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Additional studies on side effects of melperone in long-term therapy for 1-20 years in psychiatric patients.
    Christensen I; Geismar L; Kirkegaard A; Kirkegaard G
    Arzneimittelforschung; 1986 May; 36(5):855-60. PubMed ID: 2873821
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A comparison of two doses of melperone, an atypical antipsychotic drug, in the treatment of schizophrenia.
    Sumiyoshi T; Jayathilake K; Meltzer HY
    Schizophr Res; 2003 Jul; 62(1-2):65-72. PubMed ID: 12765745
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Side effects of methylperone in long-term therapy up to 8 years].
    Kirkegaard G; Kirkegaard A
    Arzneimittelforschung; 1974 Aug; 24(8):1115-7. PubMed ID: 4213783
    [No Abstract]   [Full Text] [Related]  

  • 5. Melperone, an aytpical antipsychotic drug with clozapine-like effect on plasma prolactin: contrast with typical neuroleptics.
    Bobo WV; Jayathilake K; Lee MA; Meltzer HY
    Hum Psychopharmacol; 2009 Jul; 24(5):415-22. PubMed ID: 19551763
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Using antipsychotic agents in older patients.
    Alexopoulos GS; Streim J; Carpenter D; Docherty JP;
    J Clin Psychiatry; 2004; 65 Suppl 2():5-99; discussion 100-102; quiz 103-4. PubMed ID: 14994733
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Clinical factors related to gains in body mass index (BMI) among patients under long-term antipsychotic treatment].
    Koga M
    Seishin Shinkeigaku Zasshi; 2003; 105(4):473-88. PubMed ID: 12806910
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Prevalence and type of dermatologic disorders in psychiatric patients treated with psychotropic drugs].
    Murak-Kozanecka E; Rabe-Jabłońska J
    Psychiatr Pol; 2004; 38(3):491-505. PubMed ID: 15199658
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Movement disorders associated with neuroleptic treatment.
    Wirshing WC
    J Clin Psychiatry; 2001; 62 Suppl 21():15-8. PubMed ID: 11584982
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The clinical association of tardive dyskinesia and drug-induced parkinsonism.
    Wolf ME; Chevesich J; Lehrer E; Mosnaim AD
    Biol Psychiatry; 1983 Oct; 18(10):1181-8. PubMed ID: 6140032
    [No Abstract]   [Full Text] [Related]  

  • 11. Melperone in low doses in anxious neurotic patients. A double-blind placebo-controlled clinical study.
    Pöldinger WJ
    Neuropsychobiology; 1984; 11(3):181-6. PubMed ID: 6147789
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Prescribing patterns of antipsychotics in 13 French psychiatric hospitals].
    Bret P; Bret MC; Queuille E
    Encephale; 2009 Apr; 35(2):129-38. PubMed ID: 19393381
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The influence of the CYP2D6 polymorphism on psychopathological and extrapyramidal symptoms in the patients on long-term antipsychotic treatment.
    Plesnicar BK; Zalar B; Breskvar K; Dolzan V
    J Psychopharmacol; 2006 Nov; 20(6):829-33. PubMed ID: 16478753
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The pharmacological management of aggressive and autoaggressive behaviour in mentally retarded patients with melperone (author's transl)].
    Hacke W
    Pharmakopsychiatr Neuropsychopharmakol; 1980 Jan; 13(1):20-4. PubMed ID: 6102772
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Neuroleptic-induced movement disorders: historical perspectives].
    Wolf MA; Yassa R; Llorca PM
    Encephale; 1993; 19(6):657-61. PubMed ID: 12404786
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Psychotropic drug use in older people with mental illness with particular reference to antipsychotics: a systematic study of tolerability and use in different diagnostic groups.
    Curran S; Turner D; Musa S; Wattis J
    Int J Geriatr Psychiatry; 2005 Sep; 20(9):842-7. PubMed ID: 16116576
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevalence, utilization patterns, and predictors of antipsychotic polypharmacy: experience in a multistate Medicaid population, 1998-2003.
    Morrato EH; Dodd S; Oderda G; Haxby DG; Allen R; Valuck RJ
    Clin Ther; 2007 Jan; 29(1):183-95. PubMed ID: 17379060
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A review of liver function tests during treatment with atypical antipsychotic drugs: a chart review study.
    Atasoy N; Erdogan A; Yalug I; Ozturk U; Konuk N; Atik L; Ustundag Y
    Prog Neuropsychopharmacol Biol Psychiatry; 2007 Aug; 31(6):1255-60. PubMed ID: 17600607
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predicting the long-term risk of tardive dyskinesia in outpatients maintained on neuroleptic medications.
    Glazer WM; Morgenstern H; Doucette JT
    J Clin Psychiatry; 1993 Apr; 54(4):133-9. PubMed ID: 8098030
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clozapine maintenance therapy in schizophrenia.
    Gaszner P; Makkos Z
    Prog Neuropsychopharmacol Biol Psychiatry; 2004 May; 28(3):465-9. PubMed ID: 15093952
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.